Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Solanezumab To Solithromycin: What To Watch For In Q4

Executive Summary

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

Advertisement

Related Content

Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Xultophy Expands Label In Europe As First US Approval Decision Looms
Sanofi/Regeneron's Sarilumab Faces Stiff Competition Despite Humira Triumph
Roche's Ocrelizumab Strengthens Lead In Primary Progressive MS
Gilead's New Hep B Treatment Shows Safety Benefit But Is It Enough?
Ocrelizumab Shines At ECTRIMS With Standout Data
ICAAC 2015: Cempra CEO Sees Solithromycin Potential Beyond Infectious Diseases
Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential
Beta amyloid market prospects still no clearer after AAIC analyses

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel